Mi-RNA and COVID-19

NCT ID: NCT06881160

Last Updated: 2025-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease, characterized by respiratory failure, shock and multi-organ dysfunction requiring admission in the intensive care unit (ICU).

The aim of the present study is to analyze miRNAs associated with SARS-CoV-2 infection, disease severity and mortality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild Respiratory Failure Covid-19

Patients with Covid-19 and mild respiratory failure defined as PaO2/FiO2 201-300 mm Hg

mi-RNA analysis

Intervention Type DIAGNOSTIC_TEST

To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.

Severe Respiratory Failure Covid-19

Patients with Covid-19 and severe respiratory failure defined as PaO2/FiO2 ≤100 mm Hg.

mi-RNA analysis

Intervention Type DIAGNOSTIC_TEST

To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mi-RNA analysis

To identify biomarkers that could predict the risk of a worsened COVID-19 disease progression.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years
* diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngeal swabs

Exclusion Criteria

* pregnant women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

TINELLI GIOVANNI

Associate Professor of Vascular Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, RM, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giovanni Tinelli

Role: primary

0039 0630157205

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3155

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

B Cell Responses in COVID-19
NCT06891170 COMPLETED
Characterizing Myositis With 68Ga-FAPI PET/CT
NCT05952531 UNKNOWN EARLY_PHASE1